CO2021011140A2 - Anticuerpos que reconocen tau - Google Patents

Anticuerpos que reconocen tau

Info

Publication number
CO2021011140A2
CO2021011140A2 CONC2021/0011140A CO2021011140A CO2021011140A2 CO 2021011140 A2 CO2021011140 A2 CO 2021011140A2 CO 2021011140 A CO2021011140 A CO 2021011140A CO 2021011140 A2 CO2021011140 A2 CO 2021011140A2
Authority
CO
Colombia
Prior art keywords
antibodies
tau
recognize tau
recognize
specifically bind
Prior art date
Application number
CONC2021/0011140A
Other languages
English (en)
Inventor
Tarlochan S Nijjar
Robin Barbour
Svetlana Alexander
Iii Philip James Dolan
Stephen Jed Tam
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CO2021011140A2 publication Critical patent/CO2021011140A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona anticuerpos que se unen específicamente a tau. Los anticuerpos inhiben o retrasan patologías relacionadas con tau y deterioro sintomático relacionado.
CONC2021/0011140A 2019-02-08 2021-08-24 Anticuerpos que reconocen tau CO2021011140A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962803334P 2019-02-08 2019-02-08
US201962813124P 2019-03-03 2019-03-03
US201962855434P 2019-05-31 2019-05-31
PCT/US2020/017357 WO2020163817A1 (en) 2019-02-08 2020-02-07 Antibodies recognizing tau

Publications (1)

Publication Number Publication Date
CO2021011140A2 true CO2021011140A2 (es) 2021-09-20

Family

ID=71947192

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0011140A CO2021011140A2 (es) 2019-02-08 2021-08-24 Anticuerpos que reconocen tau

Country Status (14)

Country Link
US (1) US20220275067A1 (es)
EP (1) EP3921343A4 (es)
JP (1) JP2022520672A (es)
KR (1) KR20210125037A (es)
CN (1) CN113597431A (es)
AU (1) AU2020219374A1 (es)
BR (1) BR112021015501A2 (es)
CA (1) CA3128392A1 (es)
CO (1) CO2021011140A2 (es)
IL (1) IL285444A (es)
MX (1) MX2021009440A (es)
PE (1) PE20211709A1 (es)
SG (1) SG11202106717PA (es)
WO (1) WO2020163817A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
KR20240032953A (ko) * 2021-07-09 2024-03-12 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기 위한 그의 용도
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018546A2 (en) * 1999-09-09 2001-03-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Screening for inhibitors of 'paired helical filaments'
US8754034B2 (en) * 2009-02-06 2014-06-17 The Regents Of The University Of California Structure-based design of peptide inhibitors of amyloid fibrillation
US8703137B2 (en) * 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
CN109265543B (zh) * 2011-09-19 2022-04-26 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
WO2013059786A1 (en) * 2011-10-21 2013-04-25 The Ohio State University Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CU24446B1 (es) * 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
MX2017015464A (es) * 2015-06-05 2018-03-28 Genentech Inc Anticuerpos anti-tau y metodos de uso.
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2018156250A1 (en) * 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)

Also Published As

Publication number Publication date
SG11202106717PA (en) 2021-07-29
WO2020163817A1 (en) 2020-08-13
KR20210125037A (ko) 2021-10-15
EP3921343A4 (en) 2022-12-14
PE20211709A1 (es) 2021-09-01
US20220275067A1 (en) 2022-09-01
BR112021015501A2 (pt) 2021-10-19
CA3128392A1 (en) 2020-08-13
IL285444A (en) 2021-09-30
CN113597431A (zh) 2021-11-02
AU2020219374A1 (en) 2021-07-01
EP3921343A1 (en) 2021-12-15
JP2022520672A (ja) 2022-03-31
MX2021009440A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
CO2021011140A2 (es) Anticuerpos que reconocen tau
CO2019013265A2 (es) Anticuerpos que reconocen tau
UY38601A (es) Anticuerpos que reconocen tau
CO2018012986A2 (es) Anticuerpos que reconocen tau
CO2018012987A2 (es) Anticuerpos que reconocen tau
CO2021007370A2 (es) Anticuerpos que reconocen tau
CU20210039A7 (es) Anticuerpos que reconocen tau
CU24446B1 (es) Un anticuerpo monoclonal humanizado que se une a tau
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
JP1763462S (ja) スマートフォンケース
AR122736A1 (es) Anticuerpos que reconocen sortilina
EA202191306A1 (ru) Антитела, распознающие тау
AR128076A1 (es) Anticuerpos que reconocen la sortilina
MX2021010517A (es) Anticuerpos que reconocen tau.
CY2023014I2 (el) Αντι il-36r αντισωματα
JP1752306S (ja) 書類ケース
JP1745429S (ja) 書類ケース
JP1745428S (ja) 書類ケース
JP1745431S (ja) 書類ケース
EA202192113A1 (ru) Антитела, распознающие тау
TH193847S (th) อุปกรณ์ตอนกิ่ง
JP1765063S (ja) スマホケース
JP1719202S (ja) ボックスファイル
JP1719186S (ja) ボックスファイル
ES2970228T3 (es) Bulto